Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

Contributed by: PR Newswire

Tags

Orphan-Therapeutics-A

More Like This

SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies

Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases

Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments

Business Wire logo

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

PR Newswire associated0

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

PR Newswire associated0

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab